Rob Surgical, the spin-off created by IBEC and the UPC, closes a €5 million investment round with Scranton Enterprises

Rob Surgical, the spin-off created by the Institute for Bioengineering of Catalonia (IBEC) and the Polytechnic University of Catalonia (UPC) in 2012, has closed a €5 million investment round with the Dutch holding Scranton Enterprises to fund the final phase of the new Bitrack System and launch the product onto the market

Rob Surgical is a company which designs and develops new robotic systems for minimally invasive surgery. The investment will facilitate the obtention of the CE marking for the new Bitrack System, which will enable it’s break into the market to improve the effectiveness of current surgical robotics.

The Bitrack System will be an alternative to the current laparoscopy surgical robot Da Vinci and will be an improvement on what is currently available in terms of efficiency.

Read more…

“Our value proposition that differentiates us from other surgical robots is based on three cornerstones: high precision benefiting the patient, superior usability for the surgeon and a significant total cost of ownership reduction benefiting hospitals”, explains Amat, CEO of Rob Surgical and president of CataloniaBio & HealthTech.

To achieve this, the Rob Surgical engineers, led by the professors Josep Amat and Alícia Casals, IBEC associated researcher, have designed a flexible, modular and open robotic platform that “will improve the effectiveness of today’s robotic surgery and make it accessible to more hospitals around the world”, adds Jaume Amat. “We will make possible combined manual and robotic surgery, what we like to call hybrid mininum invasive surgery (HMIS)” says Amat.

The new robot has already been technically validated in experimental models, used by surgeons from the Mayo Clinic (United States) and the Barcelona university hospitals Clinic, Vall d’Hebron and Germans Trias. Between 2019 and 2021 Rob Surgical will build three new units to finalise the validation and industrialisation process to expand the corporate and engineering team and will conduct the final safety and functionality trials.